SLC5A2 and autosomal dominant polycystic kidney disease: Dapagliflozin is a selective SGLT2 inhibitor that increases glucose excretion and urine output; however, in the PCK rat model of PKD, dapagliflozin treatment led to increases in cyst volume and kidney weight, suggesting that SGLT2 inhibition may have complex effects in ADPKD [121].